论文部分内容阅读
目的:通过海藻与甘草不同比例配伍的海藻玉壶汤对甲状腺肿大大鼠模型心、肾功能相关指标的检测,筛选海藻与甘草反药组合配伍使用的宜忌条件。方法:按“973”项目组规定的SOP,将海藻与甘草按照2因素7水平的均匀设计实验原则设置不同配伍比例,观察海藻与甘草不同配比的海藻玉壶汤对甲状腺肿大大鼠模型肌酐、尿素氮、肌酸激酶、乳酸脱氢酶以及心、肾组织病理形态的影响。结果:模型组及给药组的肌酐(Cr)、尿素氮(BUN)含量均未见明显异常,与模型组比较,配比六组(29.04∶4.16)、七组(24.20∶10.40)血清中血钾水平显著升高,血钠水平显著降低(P<0.05);心肌酶水平的变化,阳性药组及各给药组CK水平较模型组显著降低(P<0.05),且降低程度有一定的随着海藻用量的增加而减弱的趋势。配比二组(9.68∶12.49)、三组(19.36∶0.54)、阳性药组具有一定程度的病理形态的改变,但各给药组未表现出较模型组加重的趋势。结论:含海藻与甘草不同配伍比例的复方海藻玉壶汤对甲状腺肿大大鼠模型的心、肾功能无明显影响,是否属于毒性作用有待进一步验证。
OBJECTIVE: To detect the related indexes of heart and kidney function of seaweed and licorice with different proportions of seaweed juguitang and to select the appropriate conditions for compatibility of seaweed and licorice anti-drug combination. Methods: According to the SOP stipulated in the “973 ” project group, different proportion of seaweed and licorice were set according to the principle of uniform design of 2 factors and 7 levels. The effect of seaweed and licorice with different ratios of seaweed and Yuhu soup on goiter rats Model creatinine, blood urea nitrogen, creatine kinase, lactate dehydrogenase, as well as heart and kidney pathological changes. Results: The levels of creatinine (Cr) and blood urea nitrogen (BUN) in the model group and the administration group were not significantly different. Compared with the model group, the six groups (29.04:4.16) and the seven groups (24.20:10.40) (P <0.05). The level of myocardial enzymes, the positive drug group and each administration group were significantly lower than the model group (P <0.05), and the degree of reduction was certain With the increase of the amount of seaweed weakened. The two groups (9.68:12.49), three groups (19.36:0.54), the positive drug group has a certain degree of pathological changes, but each drug group did not show more than the model group increased the trend. CONCLUSION: Fufang Haiyu Yuhu soup with different compatibility ratios of seaweed and licorice has no obvious effect on heart and kidney function of goiter rats. Whether it is toxic or not needs further verification.